Wound Injector with Multi-Agent Hemostasis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
In emergency medicine, uncontrolled bleeding during the 'golden hour' following severe trauma poses a significant challenge in maximizing patient survival, as existing methods are inadequate for immediate and effective bleeding control on scene or en route to a medical facility.
Innovation Solution
A wound injector apparatus comprising a clotting factor, an expandable biocompatible material, and a thermal agent, housed in separate chambers with a propellant system and nozzle configuration, allowing controlled discharge and application to slow down bleeding through clotting, pressure application, and thermal management.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional bleeding control methods are used, then the treatment can be simple to apply, but the effectiveness in stopping severe bleeding is inadequate
Solution Approach 1:
The wound injector is divided into multiple separate chambers, each containing a different hemostatic agent (clotting factor, expandable material, thermal agent). This segmentation allows each component to be optimized for its specific function while maintaining overall effectiveness, resolving the contradiction between reliability and complexity by organizing the complex system into manageable, specialized modules.
Solution Approach 2:
The invention combines multiple hemostatic mechanisms (chemical clotting, physical expansion, thermal action) into a single integrated wound injector device. This merging of different approaches enhances bleeding control effectiveness while presenting a unified, relatively simple device for application, thus resolving the contradiction between reliability and complexity.
2Reliability
If multiple hemostatic agents are used together, then the bleeding control effectiveness is improved, but the device complexity increases
Solution Approach 1:
The wound injector is designed as a multi-functional device that can deliver different hemostatic agents (clotting factors, expandable materials, thermal agents) through a single integrated system. This universality allows the device to address various types of bleeding scenarios with one apparatus, improving effectiveness without proportionally increasing complexity.
Solution Approach 2:
The invention uses propellant chambers and pressure systems to automatically dispense multiple hemostatic agents from separate chambers through nozzles. This pneumatic/hydraulic mechanism simplifies the delivery of multiple agents by using pressure-driven flow control, reducing the operational complexity despite having multiple chambers and agents.
3Loss of time
If immediate treatment is applied during the golden hour, then the survival chances are improved, but the treatment must be complex to address severe trauma
Solution Approach 1:
The wound injector is pre-loaded with multiple hemostatic agents in separate chambers before use. This preliminary preparation allows immediate treatment of severe bleeding without requiring time to assemble or prepare different components during the critical golden hour, thus reducing time loss while maintaining the capability to deliver complex multi-agent therapy.
Solution Approach 2:
The device is designed to be self-contained and self-operating, with propellant systems that automatically dispense the appropriate hemostatic agents when activated. This self-service capability eliminates the need for complex manual preparation or multiple separate applications, enabling immediate treatment while simplifying the operational process during emergency situations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The wound injector effectively slows down bleeding by applying clotting factors, physical pressure, and thermal agents, enhancing the chances of survival by providing immediate and controlled treatment during the critical 'golden hour' period.
Implementation Method 1
The propellant may include at least one of O2, CO2 and N2
Implementation Method 2
a thermal agent, allowing controlled discharge and application to slow down bleeding through clotting, pressure application, and thermal management
Implementation Method 3
an expandable biocompatible material, housed in separate chambers with a propellant system
Implementation Method 4
A wound injector apparatus comprising a clotting factor
Data Source
AI summary
A wound injector apparatus is described. The wound injector includes a clotting factor, an expandable material, a thermal agent, a chamber, and a nozzle. At least one chamber houses the clotting factor, the expandable factor and the thermal agent. Additionally, at least one nozzle is configured to discharge at least one of the clotting factor, the expandable material, and the thermal agent.